Product Description
ATG-037 is a highly potent, selective, orally-bioavailable small molecule inhibitor of CD73 that has best-in-class potential as either a monotherapy or in combination against a range of tumor types. It overcomes the 'hook-effect' of clinical anti-CD73 antibodies and could completely block CD73 activity in vitro. (Sourced from: https://www.antengene.com/news/1496.html)
Mechanisms of Action: CD73 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Antengene Therapeutics
Company Location: Asia Pacific
Company Founding Year: 2017
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05205109 |
ATG-037-001 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-08-30 |
12% |
2024-05-01 |
Primary Endpoints|Treatments |
CTR20223400 |
CTR20223400 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |